Javle M, et al. - In a multicenter, open-label, phase II study, researchers examine BGJ398 antitumor activity in patients age ≥ 18 years with advanced or metastatic cholangiocarcinoma containing Fibroblast growth factor receptor 2 (FGFR2) fusions or other FGFR alterations whose disease had progressed while receiving prior therapy. With manageable toxicities, BGJ398 is a first-in-class FGFR kinase inhibitor. It demonstrates meaningful clinical activity against chemotherapy-refractory cholangiocarcinoma containing FGFR2 fusions. In this highly selected patient population, continued development of BGJ398 is supported by the promising results.